Support The Ponder News:
"This is some promising news in the midst of this COVID-19 situation," said Daniel Simon, MD, Chief Clinical & Scientific Officer and President, UH Cleveland Medical. "Our UH research team has worked closely with the manufacturer, Gilead, in recent days to secure the studies. We are grateful to be one of the first sites in the U.S. to participate in these clinical trials. Both trials are now approved by the U.S. Food and Drug Administration (FDA) and our Institutional Review Board, and we are expecting shipment of the experimental drug remdesivir in the next couple of days."